Abstract：Objective To investigate the relationship between human papillomavirus (HPV) infection/p16 expression and radiotherapy prognosis in oropharyngeal squamous cell carcinoma (OSCC) and the prognostic value of p16 in OSCC patients treated with radiotherapy. Methods Tissue samples were collected from 42 patients newly diagnosed with OSCC in our hospital from January 1999 to December 2008. PCR was performed to detect HPV DNA, and p16 expression was measured by immunohistochemistry. The chi-square test was used to compare the local/regional control rate (CR) between HPV (+)/p16(+) patients and HPV (－)/p16(－) patients after radical radiotherapy and evaluate the association between HPV infection and p16 expression;the Kaplan-Meier method was used to calculate overall survival (OS), and the log-rank test was used for survival difference analysis. Results The follow-up rate was 100%. The HPV infection rate was 19%, and the positive rate of p16 was 43%. In patients who received radical radiotherapy, the local CR for HPV (+) patients was 100%, versus 54% for HPV (－) patients (P=0.026);the local CR for p16(+) patients was 92%, versus 44% for p16(－) patients (P=0.006);the locoregional CR for p16(+) patients was 69%, versus 22% for p16(－) patients (P=0.009). For high-risk patients, HPV infection was significantly associated with p16 expression (P=0.000). The 3-year OSrates for p16(+) and p16(－) patients were 91% and 26%, respectively (P=0.001). ConclusionsThe p16 expression is closely associated with HPV infection in OSCC patients, and it is expected to become one of the prognostic markers in OSCC patients treated with radiotherapy.
Qu Yuan,Gao Li,Yi Junlin et al. Relationship between HPV infection/p16 expression and radiotherapy prognosis in oropharyngeal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2014, 23(2): 135-139.
[1] Habbous S, Chu KP, Qiu X,et al. The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer Centre[J]. Cancer Epidemiol,2013,37:820-829. [2] Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer[J]. N Engl J Med,2010,363:24-35. [3] Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324:a subset analysis from an international phase Ⅲ trial[J]. Ann Oncol,2011,22:1071-1077. [4] Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial[J]. J Natl Cancer Inst,2008,100:261-269. [5] Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase Ⅲ trial[J]. J Clin Oncol,2010,28:4142-4148. [6] Lindh M, Grander S, Andersson E, et al. Real-time Taqman PCR targeting 14 human papilloma virus types[J].J Clin Virol,2007,40:321-324. [7] Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer[J]. Int J Cancer,2007,120:1731-1738. [8] Wang H, Sun R, Lin H, et al. p16(INK4A) as a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma:consideration of some aspects[J]. Cancer Sci,2013,104:1553-1559. [9] Fischer CA, Zlobec I, Green E,et al. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality[J]? Int J Cancer,2010,126:1256-1262. [10] Chen AM,Li J,Beckett LA,et al. Differential response rates to irradiation among patients with human papillomavirus positive and negative oropharyngeal cancer [J]. Laryngoscopy,2013,123:152-157. [11] Weinberger PM, Yu Z, Haffty BG, et al. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer[J]. Clin Cancer Res,2004,10:5684-5691. [12] Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324:a subset analysis from an international phase Ⅲ trial[J].Ann Oncol,2011,22:1071-1077. [13] Park WS, Ryu J, Cho KH, et al. Human papillomavirus in oropharyngeal squamous cell carcinomas in Korea:use of G1 cycle markers as new prognosticators[J]. Head Neck,2012,34:1408-1417. [14] Weinberger PM, Yu. Z, Haffty BG, et al. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer[J].Clin Cancer Res,2004,10:5684-5691. [15] Kimple RJ, Smith MA, Blitzer GC, et al. Enhanced radiation sensitivity in HPV-positive head and neck cancer[J]. Cancer Res,2013,73:4791-4800. [16] Fischer CA, Kampmann M, Zlobec I, et al. p16 expression in oropharyngeal cancer:its impact on staging and prognosis compared with the conventional clinical staging parameters[J]. Ann Oncol,2010,21:1961-1966. [17] Rieckmann T, Tribius S, Grob TJ, et al. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity[J]. Radiother Oncol,2013,107:242-246.
2014, Vol. 23 
